Search Within

Ahmet Zehir

Formats
  1. Meeting Abstract (179)
  2. Journal Article (151)
  3. Review (6)
  4. Research Letter (5)
  5. Editorial (3)
  6. Guidelines (1)
Groups
  1. Department of Pathology and Laboratory Medicine (301)
  2. GSK Faculty (288)
  3. Human Oncology and Pathogenesis Program (275)
  4. Department of Medicine (252)
  5. Solid Tumor Oncology Division (226)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (218)

More Groups

People
  1. Michael Berger (191)
  2. Marc Ladanyi (177)
  3. Maria Arcila (126)
  4. David Solit (103)
  5. David Hyman (75)
  6. Ryma Benayed (75)

More People

Years
  1. 2025 (3)
  2. 2024 (6)
  3. 2023 (6)
  4. 2022 (30)
  5. 2021 (37)
  6. 2020 (51)

More Years

Publications
  1. Journal of Molecular Diagnostics (58)
  2. Journal of Clinical Oncology (47)
  3. Cancer Research (29)
  4. Modern Pathology (28)
  5. Laboratory Investigation (19)
  6. JCO Precision Oncology (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (67)
  2. Elsevier Science, Inc. (60)
  3. American Association for Cancer Research (59)
  4. Nature Publishing Group (42)
  5. Nature Research (30)
  6. American Society of Hematology (16)

More Publishers

Results (345)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Recurrent, truncating SOX9 mutations are associated with KRAS and PI3K pathway mutations and may be oncogenic in colorectal carcinoma
    Meeting Abstract

    Hechtman, J.; Javier, B. M.; Vakiani, E.; Shia, J.; Zehir, A.; Iacobuzio-Donahue, C.
    Modern Pathology (2016)

    Fulltext@MSK | Save
  • 20q gain is an oncogenic driver event that occurs preferentially in KRAS/ BRAF wild type colorectal carcinoma
    Meeting Abstract

    Pagan, C.; Ptashkin, R.; Zehir, A.; Berger, M. F.; Shia, J. R.; Vakiani, E.; Ladanyi, M.; Hechtman, J.
    Modern Pathology (2016)

    Fulltext@MSK | Save
  • Analysis of estrogen receptor (ER) immunohistochemistry (IHC) in breast cancer with ESR1 mutations detected by hybrid capture-based next generation sequencing (NGS)
    Meeting Abstract

    Ross, D. S.; Konno, F.; Brogi, E.; Zehir, A.; Berger, M. F.; Chandarlapaty, S.; Razavi, P.; Baselga, J.; Wen, H. Y.
    Modern Pathology (2016)

    Fulltext@MSK | Save
  • Follicular dendritic cell sarcomas: Insights into its molecular landscape
    Meeting Abstract

    Jour, G.; Zehir, A.; Gounder, M. M.; Abdel-Wahab, O.; Casanova, J.; Dogan, A.; Ladanyi, M.; Klimstra, D.; Arcila, M. E.
    Modern Pathology (2016)

    Fulltext@MSK | Save
  • 20q gain is an oncogenic driver event that occurs preferentially in KRAS/BRAF wild type colorectal carcinoma
    Meeting Abstract

    Pagan, C.; Ptashkin, R.; Zehir, A.; Berger, M. F.; Shia, J.; Vakiani, E.; Ladanyi, M.; Hechtman, J.
    Laboratory Investigation (2016)

    Fulltext@MSK | Save
  • Recurrent, truncating SOX9 mutations are associated with KRAS and PI3K pathway mutations and may be oncogenic in colorectal carcinoma
    Meeting Abstract

    Hechtman, J.; Javier, B. M.; Vakiani, E.; Shia, J.; Zehir, A.; Iacobuzio-Donahue, C.
    Laboratory Investigation (2016)

    Fulltext@MSK | Save
  • Analysis of estrogen receptor (ER) immunohistochemistry (IHC) in breast cancer with ESR1 mutations detected by hybrid capture-based next generation sequencing (NGS)
    Meeting Abstract

    Ross, D. S.; Konno, F.; Brogi, E.; Zehir, A.; Berger, M. F.; Chandarlapaty, S.; Razavi, P.; Baselga, J.; Wen, H. Y.
    Laboratory Investigation (2016)

    Fulltext@MSK | Save
  • Follicular dendritic cell sarcomas: Insights into its molecular landscape
    Meeting Abstract

    Jour, G.; Zehir, A.; Gounder, M. M.; Abdel-Wahab, O.; Casanova, J.; Dogan, A.; Ladanyi, M.; Klimstra, D.; Arcila, M. E.
    Laboratory Investigation (2016)

    Fulltext@MSK | Save
  • Translational bioinformatics and clinical research (biomedical) informatics
    Journal Article

    Sirintrapun, S. J.; Zehir, A.; Syed, A.; Gao, J.; Schultz, N.; Cheng, D. T.
    Clinics in Laboratory Medicine (2016)

    Fulltext@MSK | Save
  • Clinically adoption of MSK-IMPACT, a hybridization capture-based next generation sequencing assay, for the assessment of lung adenocarcinomas
    Meeting Abstract

    Arcila, M. E.; Zehir, A.; Yu, H.; Drilon, A.; Li, B. T.; Riely, G. J.; Rekhtman, N.; Lin, O.; Hyman, D.; Berger, M.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save